Humanized neuraminidase antibody and methods of use thereof

• US 9,115,201 B2
• Filed: 04/16/2014
• Issued: 08/25/2015
• Est. Priority Date: 09/28/2008
• Status: Active Grant

• Current Assignee: iBio, Inc.
• Original Assignee: iBio, Inc.
• Inventors: Yusibov, Vidadi, Mett, Vadim, Shoji, Yoko
• Primary Examiner(s): Lucas, Zachariah
• Assistant Examiner(s): Salvoza, M. Franco
• Application Number:
  US14/254,176
• Publication Number:
  US 20140314754A1
• Time in Patent Office: 496 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: C07K 16/1018 Orthomyxoviridae, e.g. influenza virus
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/41 Glycosylation, sialylation, or fucosylation
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Antibodies against influenza neuraminidase, compositions containing the antibodies, and methods of using the antibodies are provided herein.

Claims

1. A method for treating an influenza infection in a subject in need thereof, comprising administering to the subject an amount a composition that is effective to reduce symptoms of the influenza infection in the subject, wherein the composition comprises a pharmaceutically acceptable carrier and an antibody that binds neuraminidase, wherein the antibody has the ability to inhibit neuraminidase enzyme activity, and wherein the antibody comprises the light chain amino acid sequence set forth in SEQ ID NO:

9 or SEQ ID NO;

10, and wherein the antibody comprises the heavy chain amino acid sequence set forth in SEQ ID NO;

7 or SEQ ID NO;

8.

2. The method of claim 1, wherein the subject is a human patient.

3. The method of claim 2, wherein the human patient is diagnosed as having influenza.

4. The method of claim 3, wherein the human patient is diagnosed as having an oseltamivir-resistant strain of influenza.